CHMP adopts positive opinion for Filsuvez® for the treatment of Dystrophic and Junctional EB

Positive opinion based on largest ever pivotal global Phase 3 EASE study undertaken in EB Filsuvez® would be the first and only approved treatment in Europe for EB Patients

Thank you for visiting Tailwinds Research. We are pleased to offer free research on select small and micro cap companies. It is free to join and we hope you’ll take the time to do so.

To create an account please click on this link.

If you already have an account, please log in here.

LEAVE A REPLY

Please enter your comment!
Please enter your name here